Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS, Aug. 30, 2021 /PRNewswire/ -- Highlander Partners ("Highlander") today announced that it has entered into a definitive agreement under which Catalent, Inc. (NYSE: CTLT) will acquire Highlander's portfolio company, Bettera Holdings, LLC, the parent company of Bettera Brands ("Bettera"), for $1 billion.  Bettera is a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market.

Highlander Partners Announces the Signing of a Definitive Agreement to Sell Bettera Brands to Catalent

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced financial results for the fourth quarter of fiscal 2021, which ended June 30, 2021. In addition, the company also announced in a separate press release today the details of its agreement to acquire Bettera Holdings, LLC, a leading manufacturer

Catalent, Inc. Reports Fourth Quarter Fiscal 2021 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that it has reached an agreement to acquire Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market, for $1 billion, subject to customary adjustments. Currently

Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer

CTLT is set to give its latest quarterly earnings report on Monday , 2021-08-30. Here's what investors need to know before the announcement.

Preview: Catalent's Earnings

Catalent, Inc. (NYSE:CTLT) is an American company that operates in the pharmaceutical industry.

Catalent Stock Hits Record High, Eyes Five-Straight Ahead of Earnings

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q4 results.

Catalent (CTLT) to Report Q4 Earnings: What's in Store?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will release financial results for the fourth quarter of fiscal year 2021 ended June 30, 2021, before the market open on Monday, August 30, 2021. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET on

Catalent, Inc. Announces Fourth Quarter Fiscal Year 2021 Earnings Conference Webcast

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass. Catalent will purchase renewable energy certificates for all of

Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint

Crown Castle International

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

2 Stocks Insiders Are Buying

Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.

Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning

Hannon Armstrong Sustainable Infrastructure Capital

Immersion

ServiceNow

Walmart

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities.  The plant is currently filling vials of COVID-19 vaccines for AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ).

Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant

Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.

Catalent (CTLT) Inks Deal for Feasibility Study of CBD Product

Cardiff Oncology

Novocure

OncoCyte

PerkinElmer

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.

Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout

CTLT's quarterly revenue grew over 35% Y/Y, driven by its Biologics segment. Biologics provides fill-finishing for manufacturers of COVID-19 vaccines. 2021 could be a high watermark for the segment.

Catalent Is Overvalued

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that John Chiminski, Chair and Chief Executive Officer, will virtually present at the Biopharma CEO Investor Forum at 9:45 a.m. ET on June 8, 2021. A live webcast of the presentation will be accessible at http://investor.catalent.com and wi

Catalent, Inc. to Present at the Biopharma CEO Investor Forum

AstraZeneca

AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant to a factory owned by Catalent Inc (NYSE: CTLT), the New York Times reported. The company has been on the lookout for an alternative production site since the U.S. government stopped it from using Emergent's Baltimore plant after workers accidentally contaminated a batch of Johnson & Johnson's (NYSE: JNJ) vaccine with ingredients from AstraZeneca's that was also being produced at the time.

AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the Jefferies Healthcare Conference at 10:30 a.m. ET on June 1, 2021, and the William Blair 41st Annual Growth Stock Conference at 11:40 a.m. ET on June 3, 2021. A live

Catalent, Inc. to Present at the Jefferies Healthcare Conference and the William Blair Growth Stock Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the UBS Global Healthcare Virtual Conference at 11:00 a.m. ET on May 26, 2021. A live webcast of the presentation will be accessible at http://investor.catalent.com and

Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene and therapies, and consumer health products, today published its Corporate Responsibility (CR) Report for fiscal year 2020. The report covers environmental, social, and governance (ESG) topics relevant to Catalent's business, charting the company's performance against the Sustainability Accountin

Catalent Publishes Second Annual Corporate Responsibility Report Highlighting Achievements in an Extraordinary Year for the Pharmaceutical Industry

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the promotion of Thomas Castellano to serve as the company's Senior Vice President and Chief Financial Officer effective June 1, 2021, succeeding Wetteny Joseph who will be leaving the company to become the Chief Financial Officer of Zoetis

Catalent Announces Chief Financial Officer Succession

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the BofA Securities 2021 Health Care Conference at 11:45 a.m. ET on May 12, 2021. A live webcast of the presentation will be accessible at http://investor.catalent.com

Catalent, Inc. to Present at the BofA Securities 2021 Health Care Conference

Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub. Catalent has acquired Promethera's Hepatic Cell Therapy Support SA (HCTS) subsidiary and its 32,40-square-foot facility in Gosselies, Belgium.

Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts

Shares of Catalent (NYSE:CTLT) decreased 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 64.00% over the past year to $0.82, which beat the estimate of $0.74.

News for Catalent Stock (CTLT)